The prevalence of myopia and its complications has risen considerably in recent decades, particularly among children and teenagers. This trend is also spreading in Europe, driven by the increase in screen time and the intensive use of new technologies and social media, particularly among the younger generation. Several treatment options are available today, including pharmacological treatments with atropine eye drops, as well as optical myopia control systems in the form of glasses or contact lenses. These different treatments have been used in clinical practice at Saint-Étienne University Hospital since 2017 for atropine, and more recently with the development of optical myopia control systems and their combinations. Little clinical data has been published to date on these different treatment combinations in the French population. The investigators would therefore like to set up a database to publish their results and share their experience.
Study Type
OBSERVATIONAL
Enrollment
114
Demographic data collection: age, gender, level of education/study, time spent in near vision, sports practice, medical history
Ophthalmological history: age of myopia discovery, parental refraction, previous refractions, presence of a braking treatment
Ophthalmological data at each examination: visual acuity, subjective refraction, cycloplegia with SKIACOL, axial length.
Potential adverse events: halos, photophobia, stinging, infections, etc.
CHU de Saint-Étienne
Saint-Etienne, France
Database of active treatments for myopia
Database established with data from children or young adults with active myopia treated with ATROPINE 0.01% eye drops or myopia control spectacles or contact lenses, and their various combinations.
Time frame: Month 5
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.